Insider Selling: Medpace (NASDAQ:MEDP) VP Sells $4,500,000.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) VP Susan Burwig sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Medpace Stock Down 0.2%

Shares of MEDP stock opened at $577.11 on Friday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a market cap of $16.11 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15. The business’s 50 day moving average is $507.61 and its two-hundred day moving average is $493.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period in the prior year, the firm earned $3.10 EPS. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Mizuho increased their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $584.18.

Institutional Investors Weigh In On Medpace

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC increased its stake in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares during the period. Wasatch Advisors LP grew its holdings in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Invesco Ltd. increased its position in shares of Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares during the period. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.